Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction

American Heart Journal

Volumn 169, Issue 3, 2015, Pages 404-411.e3

  Gandhi, Parul U ^a   Motiwala, Shweta R ^b   Belcher, Arianna M ^a   Gaggin, Hanna K ^a   Weiner, Rory B ^a   Baggish, Aaron L ^a   Fiuzat, Mona ^c   Brunner La Rocca, Hans Peter ^d   Januzzi, James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK REDUCTION; TITRIMETRY; AGED; BLOOD; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84926210669     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.12.012     Document Type: Article

References (24)

1. M. Papaspyridonos, E. McNeill, and J.P. de Bono Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction Arterioscler Thromb Vasc Biol 28 2008 433 440
2. U.C. Sharma, S. Pokharel, and T.J. van Brakel Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
3. R.R. van Kimmenade, J.L. Januzzi Jr., and P.T. Ellinor Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
4. R.A. de Boer, D.J. Lok, and T. Jaarsma Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
5. G.M. Felker, M. Fiuzat, and L.K. Shaw Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ Heart Fail 5 2012 72 78
6. S.R. Motiwala, J. Szymonifka, and A. Belcher Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study Eur J Heart Fail 15 2013 1157 1163
7. L. Calvier, M. Miana, and P. Reboul Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler Thromb Vasc Biol 33 2013 67 75
8. R.A. de Boer, A.R. van der Velde, and C. Mueller Galectin-3: a modifiable risk factor in heart failure Cardiovasc Drugs Ther 28 2014 237 246
9. M.D. Filipe, W.C. Meijers, and A.R. van der Velde Galectin-3 and heart failure: prognosis, prediction, & clinical utility Clin Chim Acta 2014 10.1016/j.cca.2014.10.009 [Epub ahead of print]
10. C.W. Yancy, M. Jessup, and B. Bozkurt 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 2013 e240 e327
11. J.L. Januzzi Jr., S.U. Rehman, and A.A. Mohammed Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
12. A. Bhardwaj, S.U. Rehman, and A. Mohammed Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study Am Heart J 159 2010 532 538 e1
13. W.H. Tang, K. Shrestha, and Z. Shao Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival Am J Cardiol 108 2011 385 390
14. P. McCullough, R.A. de Boer, and F. Edelmann Utilization of galectin-3 in case management across the spectrum of heart failure Rev Cardiovasc Med 15 2014 197 207
15. Y. Xue, A. Maisel, and W.F. Peacock Using galectin-3 to reduce heart failure rehospitalization Future Cardiol 10 2014 221 227
16. M. Fiuzat, P.J. Schulte, and M. Felker Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION J Card Fail 20 2014 38 44
17. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
18. H.K. Gaggin, S. Motiwala, and A. Bhardwaj Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure Circ Heart Fail 6 2013 1206 1213
19. R.A. Weir, P.B. Mark, and C.J. Petrie Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157 2009 1088 1096
20. A. Maisel, Y. Xue, and D.J. van Veldhuisen Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study) Am J Cardiol 114 2014 737 742
21. H.K. Gaggin, J. Szymonifka, and A. Bhardwaj Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin t measurements in patients with chronic heart failure JACC Heart Fail 2 2014 65 72
22. R.M. Lang, M. Bierig, and R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
23. L.A. Inker, C.H. Schmid, and H. Tighiouart Estimating glomerular filtration rate from serum creatinine and cystatin C N Engl J Med 367 2012 20 29
24. T. Rector, S. Kubo, and J. Cohn Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire Heart Fail 3 1987 198 209